Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Once-daily combined abacavir/3TC pill available in the UK on a named patient basis

A fixed-dose combination pill of the nucleoside analogues (NRTIs) abacavir and 3TC is being made available, on a named patient basis, in the UK. The tablet

Published
02 March 2004
By
Michael Carter
Protein discovered that blocks HIV in monkeys: potential for vaccine and treatment research

A protein has been identified in monkey cells that can block infection with HIV, according to US research published in the February 26th edition of

Published
26 February 2004
By
Michael Carter
Expensive micronutrient formula associated with CD4 increases

A broad-spectrum micronutrient formula developed by a California HIV practitioner has been shown to significantly increase CD4 cell counts - by 25% over 12 weeks

Published
20 February 2004
By
Edwin J. Bernard
HIV attachment inhibitors: three more join the ranks at CROI

Three companies presented promising data on drugs which block the entry of HIV into cells at last week's Eleventh Conference on Retroviruses and Opportunistic Infections

Published
18 February 2004
By
Keith Alcorn
FTC has potent anti-HBV effect in HIV/HBV coinfected patients, and rate of resistance low

FTC (emtricitabine, Emtriva) has potent anti-hepatitis B virus (HBV) and anti-HIV activity when included in the HAART regimens of individuals coinfected with HBV and HIV,

Published
12 February 2004
By
Michael Carter
Vaccine research: back to the drawing board?

The major presentations on HIV vaccines at the Eleventh Conference on Retroviruses and Opportunistic Infections in San Francisco were dominated by one question. Is it

Published
12 February 2004
By
Julian Meldrum
Confusion continues at CROI over triple nuke therapy (amended)

Triple nucleoside combinations came under more scrutiny this week at the Eleventh Conference on Retroviruses and Opportunistic Infections, with still little consenus about why so

Published
11 February 2004
By
Edwin J. Bernard
Opportunities and challenges on the route to effective microbicides

A plenary presentation at the Eleventh Conference on Retroviruses and Opportunistic Infections in San Francisco by Dr Robin Shattock from St George’s Hospital Medical School,

Published
10 February 2004
By
Julian Meldrum
Gilead abandons research on salvage drug

Gilead Sciences today announced that it has decided to abandon its research programme to develop the experimental nucleoside analogue amdoxovir (DAPD). Rights to develop the

Published
28 January 2004
By
Keith Alcorn
New formulation of nelfinavir clears key hurdle on road to EU approval

A new formulation of the protease inhibitor nelfinavir (Viracept), that reduces the drug’s daily pill burden by 60% has received a positive opinion from the

Published
28 January 2004
By
Michael Carter

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.